• BRD4770: G9a Histone Methyltransferase Inhibitor in Cancer B

  2026-05-09

  BRD4770 empowers researchers to dissect the epigenetic regulation of tumorigenesis with precision, targeting G9a-mediated histone methylation. This article details experimental workflows, troubleshooting strategies, and evidence-based use-cases for BRD4770, drawing on recent advances in cancer epigenetics.

• GW4064: Non-Steroidal FXR Agonist for Metabolic Research Adv

  2026-05-08

  GW4064 enables high-precision modulation of FXR signaling, unlocking advanced experimental models for metabolic disease and fibrosis. This guide delivers actionable workflows, troubleshooting strategies, and data-backed recommendations to maximize GW4064’s impact in lipid, bile acid, and ferroptosis research.

• Selective Autophagy Regulates IRF3 Stability and IFN Signali

  2026-05-08

  Wu et al. (2021) reveal how selective autophagy, mediated by CALCOCO2/NDP52 and regulated by PSMD14, precisely controls the degradation of IRF3, a key transcription factor in antiviral immunity. Their findings clarify the crosstalk between autophagic processes and type I interferon production, offering new insights into immune regulation and potential strategies for manipulating transcription factor stability.

• BIBR 1532: Deep Mechanistic Insights into Telomerase Inhibit

  2026-05-07

  Explore the advanced molecular mechanisms of BIBR 1532, a potent telomerase inhibitor, and discover how its precise targeting of hTERT enables new strategies for cancer cell proliferation inhibition. This article uniquely connects telomerase biology, apoptosis induction, and assay decisions to empower translational oncology research.

• Cycloheximide in Translational Research: Protocols & Trouble

  2026-05-07

  Cycloheximide, a gold-standard protein biosynthesis inhibitor, enables precise and rapid dissection of translation-dependent cellular mechanisms. This article translates breakthrough findings and expert workflows into actionable steps, spotlighting troubleshooting and advanced applications for apoptosis assays, protein turnover studies, and disease modeling.

• Mitochondrial Calcium Signaling Represses Ferroptosis via GP

  2026-05-06

  This study reveals a direct mechanistic link between mitochondrial calcium uptake, mediated by the mitochondrial calcium uniporter (MCU), and suppression of ferroptotic cell death through regulation of GPX4 acetylation. The findings provide new insights into how mitochondrial metabolism modulates ferroptosis, with implications for targeting regulated cell death in disease models.

• Strategic GSK-3 Inhibition: Unleashing Organoid Innovation

  2026-05-06

  Explore how CHIR-99021 (CT99021) sets a new benchmark for translational researchers aiming to model developmental processes and steer cell fate. This thought-leadership article delivers mechanistic insight, best-practice protocol guidance, and a critical bridge to recent breakthroughs in organoid-based modeling of limb morphogenesis, spotlighting workflow advances and future opportunities enabled by APExBIO's selective GSK-3 inhibitor.

• AMC-Hem Probe Illuminates HO-1 Activity in Live Macrophages

  2026-05-05

  This study introduces AMC-Hem, a red-shifted fluorescent probe enabling real-time visualization and quantification of heme oxygenase-1 (HO-1) activity within live human macrophages. The probe's application uncovers novel regulatory mechanisms and spatial dynamics of HO-1, advancing experimental approaches for vascular and inflammatory disease research.

• Biodegradable Lipid Nanoparticles Enable Tumor-Selective mRN

  2026-05-05

  This study introduces a combinatorial library of ROS-degradable lipid nanoparticles that selectively deliver mRNA to tumor cells, exploiting elevated ROS levels for controlled intracellular release. The findings provide a promising framework for targeted mRNA therapies that can efficiently block mutant RAS signaling, with implications for advancing gene delivery strategies in cancer.

• Innovations in In Vitro Drug Response Evaluation for Cancer

  2026-05-04

  Schwartz’s dissertation introduces a rigorous framework for dissecting the interplay between proliferation arrest and cell death in cancer drug response using in vitro models. By distinguishing relative and fractional viability metrics, the study enhances precision in evaluating the effects of agents such as BET bromodomain inhibitors, with practical implications for apoptosis and growth arrest research.

• CXCR4-Targeted Theranostics in Lymphoma: Imaging and Therapy

  2026-05-04

  This review synthesizes recent advances in CXCR4-targeted imaging and therapy for lymphoma, highlighting the receptor’s role in disease aggressiveness and resistance. The paper details emerging radiotracers and therapeutic agents, outlining their mechanistic rationale, clinical potential, and workflow considerations for precision oncology.

• GANT61: Selective GLI Inhibitor for Tumor Growth Suppression

  2026-05-03

  GANT61, a potent GLI inhibitor from APExBIO, blocks GLI1/GLI2-driven transcription in the Hedgehog pathway, arresting tumor cell proliferation and reducing tumor growth in vivo. This article details its mechanism, key benchmarks, and workflow best practices for cancer research.

• Protease Inhibitor Cocktail EDTA-Free: Precision in Post-Tra

  2026-05-02

  Explore how Protease Inhibitor Cocktail EDTA-Free unlocks reproducible post-translational modification studies and advanced protein assays by preserving protein integrity without EDTA. This article offers a deeper scientific perspective and actionable insights for phosphorylation-sensitive workflows.

• EZ Cap™ Mouse IL-12 mRNA (m1Ψ): Redefining Extrahepatic Immu

  2026-05-01

  Explore how EZ Cap™ Mouse IL-12 mRNA (m1Ψ) enables next-generation immunotherapy research by overcoming delivery and stability challenges, with unique insights from recent virus-mimicking nanoparticle innovations.

• 10074-G5: Dissecting c-Myc Inhibition for Precision Oncology

  2026-05-01

  Explore how the c-Myc inhibitor 10074-G5 enables advanced cancer research, from mechanistic targeting to practical assay design. This article uniquely bridges molecular insight with actionable protocols for apoptosis and tumor regression studies.

11409 records 1/761 page Next 12345 下5页 Last page